AnaptysBio (ANAB) vs Kailera Therapeutics (KLRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kailera Therapeutics is the larger company by market cap ($1.43 billion vs $1.39 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | KLRA |
|---|---|---|
| Share price | $46.63 | $11.02 |
| Market cap | $1.39B | $1.43B |
| 1-day change | -1.62% | -4.84% |
| YTD return | +44.28% | — |
| 1-year return | +76.58% | — |
| 5-year return | +124.76% | — |
| P/E ratio (TTM) | 7.15 | — |
| Forward P/E | 8.66 | — |
| EPS (TTM) | $6.52 | $-4.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $234.60M | — |
| Revenue growth (YoY) | +157.01% | — |
| Net income (latest FY) | $-13.23M | — |
| Operating margin | 96.72% | — |
| Net margin | -5.64% | — |
| 52-week high | $72.36 | $28.23 |
| 52-week low | $26.01 | $9.76 |
| Distance from 52-week high | -35.56% | -60.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +87.11% | +290.20% |
| Average volume | 496.92K | 1.08M |
| Shares outstanding | 29.73M | 129.85M |
| Employees | — | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
ANAB vs KLRA FAQ
Which is bigger, AnaptysBio or Kailera Therapeutics?
Kailera Therapeutics (KLRA) is larger, with a market capitalization of $1.43B compared with $1.39B for AnaptysBio (ANAB).
Are AnaptysBio and Kailera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.